Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

Immune checkpoint inhibitors have emerged as a potent new class of anticancer therapy. They have changed the treatment landscape for a range of tumors, particularly those with a high mutational load. To date, however, modest results have been observed in breast cancer, where tumors are rarely hyperm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Transl Med
Autors principals: Nolan, Emma, Savas, Peter, Policheni, Antonia N., Darcy, Phillip K., Vaillant, François, Mintoff, Christopher P., Dushyanthen, Sathana, Mansour, Mariam, Pang, Jia-Min B., Fox, Stephen B., Perou, Charles M., Visvader, Jane E., Gray, Daniel H. D., Loi, Sherene, Lindeman, Geoffrey J.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5822709/
https://ncbi.nlm.nih.gov/pubmed/28592566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal4922
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars